Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. - Wikidata - awgldk - TriplyDB

Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.

Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.

http://www.wikidata.org/entity/Q37551919

about

Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats.Turning a water and oil insoluble cisplatin derivative into a nanoparticle formulation for cancer therapy.Liposomal Formulations in Clinical Use: An Updated Review.Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer.Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy Interaction of liposome-encapsulated cisplatin with biomolecules.Nanocarriers for delivery of platinum anticancer drugs.Antibacterial properties of silver nanoparticles in three different sizes and their nanocomposites with a new waterborne polyurethane.Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer.Polysilsesquioxane nanoparticles for triggered release of cisplatin and effective cancer chemoradiotherapy Nanotechnology in oncology: Characterization and in vitro release kinetics of cisplatin-loaded albumin nanoparticles: Implications in anticancer drug delivery.Rapid detection and destruction of squamous cell carcinoma of the head and neck by nano-quadrapeutics.Treatment of pleural malignancies by photo-induction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities.New potential for enhancing concomitant chemoradiotherapy with FDA approved concentrations of cisplatin via the photoelectric effect.Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists.Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes.Cisplatin Prodrug-Conjugated Gold Nanocluster for Fluorescence Imaging and Targeted Therapy of the Breast Cancer.Emergence and Utility of Nonspherical Particles in Biomedicine A platelet-mimetic paradigm for metastasis-targeted nanomedicine platforms Potential for enhancing external beam radiotherapy for lung cancer using high-Z nanoparticles administered via inhalation Cell-centric view of apoptosis and apoptotic cell death-inducing antitumoral strategies Establishment of an Experimental Breast Cancer ZHENG Model and Curative Effect Evaluation of Zuo-Jin Wan.Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy Clinical developments in nanotechnology for cancer therapy.The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.Targeting and delivery of platinum-based anticancer drugs.Exosomes in tumor microenvironment influence cancer progression and metastasis.Application of liposomal technologies for delivery of platinum analogs in oncology.Uptake and fate of surface modified silica nanoparticles in head and neck squamous cell carcinoma.Target-selective delivery and activation of platinum-based anticancer agents.Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer.Nanoparticle formulations of cisplatin for cancer therapy.

P2860

Q26744830-0EC08916-8792-4ECF-98DA-B6A8E94FAA1C Q27011482-3534124D-8870-42D1-AAF4-05012C22DC07 Q28291499-F4EDF1D4-1E15-43C6-A512-C2F07EAA3395 Q28477234-63375807-BF77-47A6-BFF2-54585F37864C Q30366990-84D05C6D-3BC9-4BA8-A7CF-DECF396B331F Q31106992-F56307B2-95C3-4518-802A-9428BA234054 Q33827802-F8A206A6-9B3A-4345-9F5E-B8C70135DFD3 Q33850427-B97236B5-35A1-4820-9A39-872C132A00EF Q33911056-400D1843-628B-42AB-A5BB-F9B82E0DD5C9 Q33915162-651C376B-B6BF-4CDF-9602-34B3BF428A14 Q34275000-03E0C324-AFF0-4ED3-9BA0-F8C5446C6032 Q34295156-C4347C39-AAE7-4753-97B5-DB86EB8D6E2F Q34338695-C34780AA-5F3F-468E-8A5F-9B5B2086D90B Q34440024-141EA6B3-81E6-4EE1-AF98-C26E7AEBB85B Q34680322-B3437E94-C469-4F24-BE2E-013F85F500E8 Q34791190-C8B95CC7-CF75-4AAE-AE24-E68A61612742 Q35157105-7E28F4E5-7700-4616-904B-E242674E9DDC Q35560212-E2F3042F-6032-4B73-81D8-8E1EA4B9E253 Q35790604-8FF81E49-128B-49F4-8A58-27F769AFE87B Q35821336-B5E297BA-A1A6-4116-905D-79CD2451FEFA Q36014101-198BF3F0-7A91-4ACE-A86B-AF5D208F8D7C Q36394925-D09469D8-6DBE-4A1B-A315-21A92FD4E6BE Q36682970-D2268B29-09D0-40D1-874B-4C11CBCA2BEE Q36723759-7B173B23-BD23-4A03-9560-31221801B69C Q36892538-B1B5A12F-6102-4DD7-AEA9-CB0A5B2BB82B Q36949458-9BFFBF99-B275-428A-9324-0140C2D0360D Q37098720-B809B51E-071C-48FD-97F9-03835D975371 Q37129849-8E795F3E-3679-4461-92D7-482BF2180D17 Q37380009-D84F17DC-B0F4-43FF-B7CC-26F709DE2187 Q37625480-4F65D359-6668-43C7-A908-85043CE0778A Q37765187-92461195-E336-4BB5-BE8D-530453759342 Q37815479-5E53516C-DBA8-4C83-A119-D3DB8E07B93E Q38050063-6AB403A3-9CCA-41B8-9CF7-23A71FFF8B1A Q38091978-D97A5251-3B50-4B87-A9D2-F2813C17DF90 Q38136184-BBFC04EB-6D5C-48AA-943C-A873F4DF98BC Q38275454-C607DFBE-B90A-408F-BBFF-EE2A24CCE8C1 Q38523600-7D25C2D8-89D0-4EE3-80F2-3F18AD01F523 Q38546964-F905E1F1-568F-4E6A-9934-53426ADC682B Q38633157-CFED3FB0-C6A2-4339-85A2-3B76CEFED86C Q38723829-E4F6CBB4-9383-4BB7-BEA2-3AA989F689E1

P2860

Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.

http://www.wikidata.org/entity/Q37551919

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.

@en

Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.

@nl

type

label

Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.

@en

Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.

@nl

prefLabel

Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.

@en

Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.

@nl

P1433

Q37551919-8039579B-788F-4436-839D-16E38ABC6FE6

P1476

Q37551919-D9DC6FA9-3F6A-4509-9751-9D2DF196CAE9

P2093

Q37551919-8AA8E279-A48B-454F-A11D-072445F20C7E

P2860

Q37551919-073160C0-1A7B-47FB-9C4A-499DE3573823

Q37551919-07C7218A-F214-4887-BE8F-88FF60D4412A

Q37551919-09458711-D353-4A6D-9102-28E435D57371

Q37551919-0AFB2A8B-CD07-424E-89C6-2558D9FE7427

Q37551919-1470852B-DF35-4C17-BAAC-8006A85245D0

Q37551919-15AF561A-014C-4AFE-9D3B-94F4904BFD68

Q37551919-220D5BBB-0A94-40D5-BEAF-9872E8CF694A

Q37551919-26A68C78-2C95-4A85-BBCD-EECE47B3DAA0

Q37551919-2F33CDC3-4DB3-4D54-94A4-08F0213AD9AE

Q37551919-367122FF-EF31-4223-9B0F-760704F746A0

P304

Q37551919-D0739E01-4B15-48A6-829B-3431D45FE7D5

P31

Q37551919-8FB12E09-92F1-4848-A085-4D342B348E38

P356

Q37551919-3F942A18-5EC2-4A9B-8D76-245C77C16C01

P407

Q37551919-55A42848-9849-477F-BC7E-87EC48559696

P433

Q37551919-32D66F64-C56F-41F1-83C6-3615BF9CFE0A

P478

Q37551919-64EC60D4-9046-498E-929B-89FF092B945E

P577

Q37551919-F4DC6BE8-82E3-4003-A69B-6EF5E62754C4

P5875

Q37551919-2F5344F6-DB13-45BC-A46D-A4626C3F762E

P698

Q37551919-17438FC4-7F52-446D-A630-2E15680AFBB4

P356

13543780903114168

P1433

Expert Opinion on Investigational Drugs

P1476

Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.

@en

P2093

Teni Boulikas

http://www.w3.org/2001/XMLSchema#string

P2860

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer.

A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer.

A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.

Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma.

Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study.

Vaccine entrapment in liposomes.

P304

1197-1218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543780903114168

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26672584

http://www.w3.org/2001/XMLSchema#string

P698

19604121

http://www.w3.org/2001/XMLSchema#string